- Home
- IRMD vs DNA Comparison
IRMD vs DNA Comparison
Compare IRMD & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- DNA
- Stock Information
- Founded
- IRMD 1992
- DNA 2008
- Country
- IRMD United States
- DNA United States
- Employees
- IRMD N/A
- DNA N/A
- Industry
- IRMD Medical/Dental Instruments
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IRMD Health Care
- DNA Health Care
- Exchange
- IRMD Nasdaq
- DNA Nasdaq
- Market Cap
- IRMD 910.4M
- DNA 731.1M
- IPO Year
- IRMD 2014
- DNA N/A
- Fundamental
- Price
- IRMD $72.51
- DNA $13.21
- Analyst Decision
- IRMD Strong Buy
- DNA Strong Sell
- Analyst Count
- IRMD 1
- DNA 1
- Target Price
- IRMD $72.00
- DNA $9.00
- AVG Volume (30 Days)
- IRMD 57.8K
- DNA 1.8M
- Earning Date
- IRMD 10-30-2025
- DNA 11-11-2025
- Dividend Yield
- IRMD 0.94%
- DNA N/A
- EPS Growth
- IRMD 10.28
- DNA N/A
- EPS
- IRMD 1.61
- DNA N/A
- Revenue
- IRMD $77,635,163.00
- DNA $230,815,000.00
- Revenue This Year
- IRMD $12.53
- DNA N/A
- Revenue Next Year
- IRMD $11.39
- DNA $14.41
- P/E Ratio
- IRMD $44.92
- DNA N/A
- Revenue Growth
- IRMD 11.73
- DNA 25.21
- 52 Week Low
- IRMD $46.86
- DNA $5.00
- 52 Week High
- IRMD $78.38
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- IRMD 53.85
- DNA 49.03
- Support Level
- IRMD $67.84
- DNA $14.63
- Resistance Level
- IRMD $78.38
- DNA $17.58
- Average True Range (ATR)
- IRMD 2.33
- DNA 1.36
- MACD
- IRMD 0.01
- DNA -0.01
- Stochastic Oscillator
- IRMD 44.32
- DNA 35.28
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.